Brief Title
Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Official Title
Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Brief Summary
Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.
Study Type
Observational
Primary Outcome
Survival
Secondary Outcome
Number of participants with Medical Research Council grade deterioration
Condition
Tuberculous Meningitis
Intervention
Linezolid
Study Arms / Comparison Groups
Background group
Description: The treatment regimen does not include linezolid throughout the treatment course.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
150
Start Date
January 1, 2018
Completion Date
June 1, 2019
Primary Completion Date
May 1, 2019
Eligibility Criteria
Inclusion Criteria: - all patients diagnosed as TBM from the electronic medical record system. Exclusion Criteria: - Does not meet the established diagnostic criteria; - Combine other pathogen central infections; - Follow-up confirmed that the final diagnosis considers other diseases (such as tumors, autoimmune encephalitis, etc.); - Our hospital has less than one week of anti-tuberculosis treatment; - Lack of information
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
, (86)18801734036, [email protected]
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT03898635
Organization ID
2017-44
Responsible Party
Principal Investigator
Study Sponsor
Huashan Hospital
Study Sponsor
, ,
Verification Date
March 2019